LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTNASDAQ🏆 #1550 by market capUS Equity
$28.77▲ $1.98 (+6.87%)
Live1h—
24h▲ 6.9%
7d▲ 8.8%
14d▲ 2.2%
30d▼ 4.8%
1y▼ 8.7%
🏦Market Cap
$1.90B
Small Cap
📈Revenue Growth (YoY)
+81.3%
High Growth
📊Gross Margin
99.0%
High
💵FCF Margin
—
⚖️P/S Ratio
1.6x
Cheap
Otter Score
60
Fair
Trading Snapshot
- Day Range
- $28.43 – $29.12
- 52-Week Range
- —
- Volume
- $2.32B
- Avg Volume
- $2.66B
- Shares Outstanding
- 65.9M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.12B
- Last Q Revenue
- $256M
- P/E Ratio
- 3.1
- P/S Ratio
- 1.6x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own LKFT
- ✓High-growth profile — revenue up +0.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$1.12B▼ −3.9% YoY
Gross Margin (TTM)
35.8%▲ +0.7% YoY
Operating Income (TTM)
$357M▼ −3.9% YoY
Free Cash Flow (TTM)
$332M▼ −3.9% YoY
About LAKEFRONT BIOTHERAPEUTIC-ADR
A company profile for LAKEFRONT BIOTHERAPEUTIC-ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
60/100
Analyst Price Target
ⓘAverage Target
$29.17
▲ +1.4% Upside
High Target$33.09
Low Target$21.66
Based on 9 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
LAKEFRONT BIOTHERAPEUTIC-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift LKFT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
LAKEFRONT BIOTHERAPEUTIC-ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.